This oral Axl kinase inhibitor was developed by Tolero Pharmaceuticals, Inc. A first-in-human phase Ia/Ib trial (NCT02729298) evaluating TP-0903 in patients with advanced solid tumors encompassing BRAF mutated melanoma patients who haven’t responded to BRAF/MEK inhibitor combination or immunotherapy is currently recruiting patients [178,179]. The gene discussed is BRAF; the disease is melanoma.